Saturday, January 25, 2025

Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen, according to results from the PhaseIII BREAKWATER trial.

from Top Health News -- ScienceDaily https://ift.tt/pKy7AWf
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Scientists rediscover lost Megalodon fossils—and reveal a 79-foot giant

Several enormous Megalodon vertebrae thought to have been destroyed in 1989 were found sitting unnoticed on a museum shelf. Their analysis s...